<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39555064</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>COVID-19 vaccine and the risk of flares in inflammatory arthritis: a systematic literature review and meta-analysis.</ArticleTitle><Pagination><StartPage>1503895</StartPage><MedlinePgn>1503895</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1503895</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1503895</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Coronavirus disease 2019 (COVID-19) vaccines aroused concerns about the risk of flares and adverse events in inflammatory arthritis (IA) since the vaccine clinical trials did not specifically investigate this subset of patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A systematic literature review and meta-analysis to summarize the data on joint disease flare and adverse events following immunization (AEFI). Two researchers independently evaluated the literature on Pubmed, Scopus, and EMBASE databases from 22<sup>nd</sup> March 2020 to 30<sup>th</sup> September 2023. A random-effects model was used to pool odds ratios (OR) (with 95% CI) for the risk of joint disease flares and adverse events. Subgroup analyses were performed to evaluate the risk of disease flare between different IA and adverse events. Heterogeneity was assessed by I<sup>2</sup> statistic.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 9874 IA patients were included in the study: 6579 (66.6%) patients affected by RA and 3295 (33.4%) spondyloarthritis (SpA). The overall rate of flares was higher in RA vs. SpA (9.1% vs. 5.3%). However, the pooled estimated analysis showed no increased risk of joint disease flare following COVID-19 vaccination in patients affected by RA vs. SpA [OR 0.88, 95% CI: 0.77-1.00]. Furthermore, a subgroup analysis showed an increased risk of joint flares in psoriatic arthritis (PsA) patients vs. RA [OR 0.79, 95% CI: 0.68-0.93, p=0.004]. The pooled estimated analysis revealed no increased risk of AEFI in patients with RA vs. SpA [1.02, 95% CI: 0.63-1.65].</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Our meta-analysis summarized the current evidence on joint disease flares and COVID-19 vaccine-associated AEFI in IA patients. Pooled analysis showed an increased risk of disease flares in PsA vs. RA patients.</AbstractText><CopyrightInformation>Copyright © 2024 Hoxha, Striani, Lovisotto, Simioni, Doria and Ramonda.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Hoxha</LastName><ForeName>Ariela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine (DIMED), Internal Medicine Division, Padova University Hospital, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Striani</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Medicine (DIMED), Padova University Hospital, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovisotto</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine (DIMED), Internal Medicine Division, Padova University Hospital, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simioni</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine (DIMED), Internal Medicine Division, Padova University Hospital, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doria</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Medicine (DIMED), Padova University Hospital, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramonda</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Medicine (DIMED), Padova University Hospital, Padova, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067251" MajorTopicYN="N">Symptom Flare Up</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">inflammatory arthritis</Keyword><Keyword MajorTopicYN="N">AEFI</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccination</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 vaccine</Keyword><Keyword MajorTopicYN="N">rheumatoid arthritis</Keyword><Keyword MajorTopicYN="N">spondyloarthritis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39555064</ArticleId><ArticleId IdType="pmc">PMC11563799</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1503895</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weaver A, Troum O, Hooper M, Koenig AS, Chaudhari S, Feng J, et al. . Rheumatoid arthritis disease activity and disability affect the risk of serious infection events in radius 1. J Rheumatol. (2013) 40:1275–81. doi: 10.3899/jrheum.121288</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.121288</ArticleId><ArticleId IdType="pubmed">23772079</ArticleId></ArticleIdList></Reference><Reference><Citation>Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology. (2013) 52:53–61. doi: 10.1093/rheumatology/kes305</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes305</ArticleId><ArticleId IdType="pubmed">23192911</ArticleId></ArticleIdList></Reference><Reference><Citation>Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. . High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. (2011) 70:785–91. doi: 10.1136/ard.2010.128637</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.128637</ArticleId><ArticleId IdType="pubmed">21288960</ArticleId></ArticleIdList></Reference><Reference><Citation>Galicia-Hernández G, Parra-Salcedo F, Ugarte-Martínez P, Contreras-Yáñez I, Ponce-de-León A, Pascual-Ramos V. Sustained moderate- to-high disease activity and higher Charlson score are predictors of incidental serious infection events in RA patients treated with conventional disease-modifying anti-rheumatic drugs: a cohort study in the treat-to-target era. Clin Exp Rheumatol. (2016) 34:261–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26939612</ArticleId></ArticleIdList></Reference><Reference><Citation>Germano V, Cattaruzza MS, Osborn J, Tarantino A, Di Rosa R, Salemi S, et al. . Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists. J Transl Med. (2014) 12:77. doi: 10.1186/1479-5876-12-77</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-12-77</ArticleId><ArticleId IdType="pmc">PMC3994399</ArticleId><ArticleId IdType="pubmed">24655394</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti F, Rezai S, Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev. (2008) 8:124–8. doi: 10.1016/j.autrev.2008.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2008.07.007</ArticleId><ArticleId IdType="pubmed">18700175</ArticleId></ArticleIdList></Reference><Reference><Citation>Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, et al. . SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients. J Autoimmun. (2020) 112:102502. doi: 10.1016/j.jaut.2020.102502</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102502</ArticleId><ArticleId IdType="pmc">PMC7832807</ArticleId><ArticleId IdType="pubmed">32527675</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortolan A, Lorenzin M, Felicetti M, Doria A, Ramonda R. Does gender influence clinical expression and disease outcomes in COVID-19? A systematic review and meta-analysis. Int J Infect Dis. (2020) 99:496–504. doi: 10.1016/j.ijid.2020.07.076</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.07.076</ArticleId><ArticleId IdType="pmc">PMC7422797</ArticleId><ArticleId IdType="pubmed">32800858</ArticleId></ArticleIdList></Reference><Reference><Citation>Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. . 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. (2020) 79:39–52. doi: 10.1136/annrheumdis-2019-215882</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215882</ArticleId><ArticleId IdType="pubmed">31413005</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis. (2002) 61:623–5. doi: 10.1136/ard.61.7.623</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.61.7.623</ArticleId><ArticleId IdType="pmc">PMC1754139</ArticleId><ArticleId IdType="pubmed">12079904</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima S, Iwamoto T, Kobayashi Y, Kato M, Takizawa F, Ida T, et al. . Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs. RMD Open. (2024) 10:e003902. doi: 10.1136/rmdopen-2023-003902</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2023-003902</ArticleId><ArticleId IdType="pmc">PMC10882334</ArticleId><ArticleId IdType="pubmed">38388170</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh JH, Lee J, Kim SH, Kwok SK, Ju JH, Park SH. Safety, and humoral and cell-mediated immune responses to herpes zoster vaccine in patients with rheumatoid arthritis. J Rheumatol. (2018) 45:465–9. doi: 10.3899/jrheum.170936</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.170936</ArticleId><ArticleId IdType="pubmed">29419465</ArticleId></ArticleIdList></Reference><Reference><Citation>Herron A, Dettleff G, Hixon B, Brandwin L, Ortbals D, Hornick R, et al. . Influenza vaccination in patients with rheumatic diseases: safety and efficacy. JAMA. (1979) 242:53–6. doi: 10.1001/jama.1979.0330001003702</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1979.0330001003702</ArticleId><ArticleId IdType="pubmed">312949</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojanovich L. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clin Dev Immunol. (2006) 13:373–5. doi: 10.1080/17402520600800820</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17402520600800820</ArticleId><ArticleId IdType="pmc">PMC2270765</ArticleId><ArticleId IdType="pubmed">17162380</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortolan A, Lorenzin M, Cosma C, Cozzi G, Padoan A, Doria A, et al. . SARS-CoV-2 infection in spondyloarthritis patients treated with biotechnological drugs: A study on serology. Front Immunol. (2021) 12:682850. doi: 10.3389/fimmu.2021.682850</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.682850</ArticleId><ArticleId IdType="pmc">PMC8226267</ArticleId><ArticleId IdType="pubmed">34177927</ArticleId></ArticleIdList></Reference><Reference><Citation>Rondaan C, Furer V, Heijstek MW, Agmon-Levin N, Bijl M, Breedveld FC, et al. . Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open. (2019) 5:e001035. doi: 10.1136/rmdopen-2019-001035</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2019-001035</ArticleId><ArticleId IdType="pmc">PMC6744079</ArticleId><ArticleId IdType="pubmed">31565247</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong W, Woon TH, Chew LC, Low A, Law A, Poh YJ, et al. . Prevalence and factors associated with flares following COVID-19 mRNA vaccination in patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: a national cohort study. Adv Rheumatol. (2023) 63:38. doi: 10.1186/s42358-023-00316-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42358-023-00316-0</ArticleId><ArticleId IdType="pubmed">37528453</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisen UM, Berner DK, Tran F, Sümbül M, Vullriede L, Ciripoi M, et al. . Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. (2021) 80:1306–11. doi: 10.1136/annrheumdis-2021-220272</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220272</ArticleId><ArticleId IdType="pmc">PMC8117443</ArticleId><ArticleId IdType="pubmed">33762264</ArticleId></ArticleIdList></Reference><Reference><Citation>Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, et al. . Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. (2021) 80:1330–8. doi: 10.1136/annrheumdis-2021-220647</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220647</ArticleId><ArticleId IdType="pubmed">34127481</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinelli FR, Favalli EG, Garufi C, Cornalba M, ColaFrancesco S, Conti F, et al. . Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine. Arthritis Res Ther. (2022) 24:21. doi: 10.1186/s13075-021-02674-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02674-w</ArticleId><ArticleId IdType="pmc">PMC8748531</ArticleId><ArticleId IdType="pubmed">35016701</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotondo C, Cantatore FP, Fornaro M, Colia R, Busto G, Rella V, et al. . Preliminary data on post market safety profiles of COVID 19 vaccines in rheumatic diseases: assessments on various vaccines in use, different rheumatic disease subtypes, and immunosuppressive therapies: A two-centers study. Vaccines. (2021) 9:730. doi: 10.3390/vaccines9070730</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9070730</ArticleId><ArticleId IdType="pmc">PMC8310114</ArticleId><ArticleId IdType="pubmed">34358147</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoulis GE, Bournia VK, Mavrea E, Evangelatos G, Fragiadaki K, Karamanakos A, et al. . COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study. Rheumatol Int. (2022) 42:31–9. doi: 10.1007/s00296-021-05039-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-05039-3</ArticleId><ArticleId IdType="pmc">PMC8569844</ArticleId><ArticleId IdType="pubmed">34739573</ArticleId></ArticleIdList></Reference><Reference><Citation>Rider LG, Parks CG, Wilkerson J, Schiffenbauer AI, Kwok RK, Noroozi Farhadi P, et al. . Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatol Oxf Engl. (2022) 61:SI143–50. doi: 10.1093/rheumatology/keac249</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac249</ArticleId><ArticleId IdType="pmc">PMC9248066</ArticleId><ArticleId IdType="pubmed">35460240</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun-Moscovici Y, Kaplan M, Braun M, Markovits D, Giryes S, Toledano K, et al. . Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis. (2021) 80:1317–21. doi: 10.1136/annrheumdis-2021-220503</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220503</ArticleId><ArticleId IdType="pubmed">34144967</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornaro M, Venerito V, Iannone F, Cacciapaglia F. Safety profile and low risk of disease relapse after BNT162b2 mRNA SARS-CoV-2 vaccination in patients with rare rheumatic diseases. J Rheumatol. (2022) 49:334–5. doi: 10.3899/jrheum.210863</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.210863</ArticleId><ArticleId IdType="pubmed">35033998</ArticleId></ArticleIdList></Reference><Reference><Citation>Striani G, Hoxha A, Lorenzin M, Cozzi G, Scagnellato L, Vangelista T, et al. . The impact of SARS-CoV-2 infection and vaccination on inflammatory arthritis: a cohort study. Front Immunol. (2023) 14:1207015. doi: 10.3389/fimmu.2023.1207015</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1207015</ArticleId><ArticleId IdType="pmc">PMC10410443</ArticleId><ArticleId IdType="pubmed">37564642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparotto M, Bindoli S, Padoan R, Cozzi G, Depascale R, Zanatta E, et al. . New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort. Clin Exp Rheumatol. (2023) 41:642–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">35930472</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagnew AF, Rausch D, Hervé C, Zahaf T, Levin MJ, Schuind A, et al. . Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatol (Oxford). (2021) 60:1226–33. doi: 10.1093/rheumatology/keaa424</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa424</ArticleId><ArticleId IdType="pmc">PMC7937016</ArticleId><ArticleId IdType="pubmed">32910152</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamani B, Moradi Hasan-Abad A, Piroozmand A, Dehghani M, Arfaatabar M, Motedayyen H. Immunogenicity and safety of the BBIBP-CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort. Immun Inflammation Dis. (2023) 11:e858. doi: 10.1002/iid3.858</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.858</ArticleId><ArticleId IdType="pmc">PMC10186999</ArticleId><ArticleId IdType="pubmed">37249277</ArticleId></ArticleIdList></Reference><Reference><Citation>MaChado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, et al. . Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. (2022) 81:695–709. doi: 10.1136/annrheumdis-2021-221490</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221490</ArticleId><ArticleId IdType="pubmed">34972811</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherian S, Paul A, Ahmed S, Alias B, Manoj M, Santhosh AK, et al. . Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey. Rheumatol Int. (2021) 41:1441–5. doi: 10.1007/s00296-021-04917-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04917-0</ArticleId><ArticleId IdType="pmc">PMC8211311</ArticleId><ArticleId IdType="pubmed">34142203</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen P, Ravichandran N, Nune A, Lilleker JB, Agarwal V, Kardes S, et al. . COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. Rheumatol (Oxford). (2022) 62:65–76. doi: 10.1093/rheumatology/keac305</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac305</ArticleId><ArticleId IdType="pmc">PMC9214139</ArticleId><ArticleId IdType="pubmed">35713499</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieske L, Kummer LYL, van Dam KPJ, Stalman EW, van der Kooi AJ, Raaphorst J, et al. . T2B! immunity against SARS-CoV-2 study group. Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases. BMC Med. (2022) 20:100. doi: 10.1186/s12916-022-02310-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02310-7</ArticleId><ArticleId IdType="pmc">PMC8889379</ArticleId><ArticleId IdType="pubmed">35236350</ArticleId></ArticleIdList></Reference><Reference><Citation>Syversen SW, Jyssum I, Tveter AT, Tran TT, Sexton J, Provan SA, et al. . Immunogenicity and safety of standard and third-dose SARS-CoV-2 vaccination in patients receiving immunosuppressive therapy. Arthritis Rheumatol. (2022) 74:1321–32. doi: 10.1002/art.42153</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42153</ArticleId><ArticleId IdType="pmc">PMC9347774</ArticleId><ArticleId IdType="pubmed">35507355</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman D, Tetzlaff J. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ. (2009) 339:b2700. doi: 10.1136/bmj.b2700</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2700</ArticleId><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available online at: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (Accessed June 20, 2024).</Citation></Reference><Reference><Citation>Higgins JPT, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, et al. . Cochrane handbook for systematic reviews of interventions. Version 6.1 (updated September 2020). eds Higgins J., Green S. The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England: John Wiley &amp; Sons Ltd. (2020).</Citation></Reference><Reference><Citation>Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. (1997) 315:629–34. doi: 10.1136/bmj.315.7109.629</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.315.7109.629</ArticleId><ArticleId IdType="pmc">PMC2127453</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Álvaro-Gracia JM, Sanchez-Piedra C, Culqui D, Rosello R, Garcia-Dorta A, Campos C, et al. . Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study. RMD Open. (2023) 9:e002936. doi: 10.1136/rmdopen-2022-002936</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002936</ArticleId><ArticleId IdType="pmc">PMC10030283</ArticleId><ArticleId IdType="pubmed">36927849</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma M, Santosa A, Fong W, Chew LC, Low AH, Law A, et al. . Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING). J Autoimmun. (2023) 134:102959. doi: 10.1016/j.jaut.2022.102959</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102959</ArticleId><ArticleId IdType="pmc">PMC9705203</ArticleId><ArticleId IdType="pubmed">36473406</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, et al. . Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. (2018) 77:annrheumdis-2018-213222–904. doi: 10.1136/annrheumdis-2018-213222</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-213222</ArticleId><ArticleId IdType="pmc">PMC5965360</ArticleId><ArticleId IdType="pubmed">29572291</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, et al. . Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. (2017) 76:1559–65. doi: 10.1136/annrheumdis-2017-211128</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211128</ArticleId><ArticleId IdType="pubmed">28468794</ArticleId></ArticleIdList></Reference><Reference><Citation>Polachek A, Korobko U, Mader-Balakirski N, Arad U, Levartovsky D, Kaufman I, et al. . Immunogenicity and safety of vaccination against seasonal 2012 influenza virus among patients with psoriatic arthritis and psoriasis. Clin Exp Rheumatol. (2015) 33:181–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25738420</ArticleId></ArticleIdList></Reference><Reference><Citation>Caso F, Ramonda R, Del Puente A, Darda MA, Cantarini L, Peluso R, et al. . Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF-α therapy. Clin Exp Rheumatol. (2016) 34:507–12.</Citation><ArticleIdList><ArticleId IdType="pubmed">26967009</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Wang H, Tam WWS. Is rheumatoid arthritis associated with reduced immunogenicity of the influenza vaccination?A systematic review and meta-analysis. Curr Med Res Opin. (2017) 33:1901–8. doi: 10.1080/03007995.2017.1329140</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2017.1329140</ArticleId><ArticleId IdType="pubmed">28489423</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchetti Gentiloni MM, Paci V, Marconi V, Gigli M, Benfaremo D, Sordillo R, et al. . SARS-COV-2 infection, vaccination, and immune-mediated diseases: results of a single-center retrospective study. Front Immunol. (2022) 13:859550. doi: 10.3389/fimmu.2022.859550</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.859550</ArticleId><ArticleId IdType="pmc">PMC8977466</ArticleId><ArticleId IdType="pubmed">35386714</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>